Studies have confirmed that high expression of TROP2 is not only found in solid tumors such as liver cancer, breast cancer, lung cancer, gastric cancer, oral cancer, thyroid carcinoma, but also affects the development and prognostic of these patients 21-28. Here, TACSTD2 is linked to thyroid gland carcinoma.